Distinct correlations between analyzed biomarkers in advanced melanoma patients with favorable vs. unfavorable clinical outcomes of anti-PD-1 therapy suggest activation of different mechanisms within the intestinal mucosa in those subgroups that may affect or mirror whole-body immunity and influence immunotherapy efficacy. The gene discussed is PDCD1; the disease is melanoma.